Leanne Munsie

1.1k total citations
22 papers, 636 citations indexed

About

Leanne Munsie is a scholar working on Psychiatry and Mental health, Molecular Biology and Neurology. According to data from OpenAlex, Leanne Munsie has authored 22 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 7 papers in Molecular Biology and 6 papers in Neurology. Recurrent topics in Leanne Munsie's work include Genetic Associations and Epidemiology (6 papers), Alzheimer's disease research and treatments (5 papers) and Dementia and Cognitive Impairment Research (5 papers). Leanne Munsie is often cited by papers focused on Genetic Associations and Epidemiology (6 papers), Alzheimer's disease research and treatments (5 papers) and Dementia and Cognitive Impairment Research (5 papers). Leanne Munsie collaborates with scholars based in United States, United Kingdom and Japan. Leanne Munsie's co-authors include Cara Ruble, Robert C. Green, Laura K. Nisenbaum, Andrew J. Saykin, Sungeun Kim, Paul M. Thompson, Michael W. Weiner, Holly Soares, Ryan M. Smith and Shannon L. Risacher and has published in prestigious journals such as Neurology, Biological Psychiatry and Journal of the American Geriatrics Society.

In The Last Decade

Leanne Munsie

20 papers receiving 626 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leanne Munsie United States	13	210	201	185	102	102	22	636
Mariangela Panebianco United Kingdom	15	145 0.7×	142 0.7×	284 1.5×	124 1.2×	43 0.4×	32	780
Xiaofeng Guo China	16	168 0.8×	283 1.4×	663 3.6×	71 0.7×	42 0.4×	39	1.1k
Chiara Cupidi Italy	15	221 1.1×	243 1.2×	114 0.6×	121 1.2×	33 0.3×	23	627
Raffaele Rocchi Italy	15	125 0.6×	107 0.5×	221 1.2×	130 1.3×	98 1.0×	35	1.0k
Miguel L. Prieto United States	17	96 0.5×	78 0.4×	576 3.1×	63 0.6×	120 1.2×	36	939
Alain Gendron Canada	17	185 0.9×	125 0.6×	610 3.3×	125 1.2×	64 0.6×	34	1.5k
Chunkui Zhou China	11	350 1.7×	269 1.3×	315 1.7×	77 0.8×	22 0.2×	27	1.1k
Jeffrey Sevigny United States	9	154 0.7×	353 1.8×	256 1.4×	61 0.6×	37 0.4×	17	876
Elena Y. Bryleva United States	12	290 1.4×	214 1.1×	116 0.6×	61 0.6×	33 0.3×	14	931

Countries citing papers authored by Leanne Munsie

Since Specialization

Citations

This map shows the geographic impact of Leanne Munsie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leanne Munsie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leanne Munsie more than expected).

Fields of papers citing papers by Leanne Munsie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leanne Munsie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leanne Munsie. The network helps show where Leanne Munsie may publish in the future.

Co-authorship network of co-authors of Leanne Munsie

This figure shows the co-authorship network connecting the top 25 collaborators of Leanne Munsie. A scholar is included among the top collaborators of Leanne Munsie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leanne Munsie. Leanne Munsie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fleisher, Adam, Leanne Munsie, David Pérahia, et al.. (2024). Assessment of Efficacy and Safety of Zagotenemab. Neurology. 102(5). e208061–e208061. 17 indexed citations

Svaldi, Diana Otero, Saima Rathore, Leanne Munsie, et al.. (2024). Evaluation of Baseline Diffusion Tensor Imaging Biomarkers in phase 2 multi‐center PROSPECT‐ALZ study. Alzheimer s & Dementia. 20(S2).

Munsie, Leanne, Adam Fleisher, M. Stauffer, et al.. (2023). Use of plasma P‐tau217 for enrichment in the Phase 2 PROSPECT‐ALZ study of LY3372689 in early symptomatic Alzheimer’s disease: Cohort selection and baseline characteristics. Alzheimer s & Dementia. 19(S21).

Chen, Chen, et al.. (2023). Wrist-worn sensor-based measurements for drug effect detection with small samples in people with Lewy Body Dementia. Parkinsonism & Related Disorders. 109. 105355–105355. 7 indexed citations

Wang, Jian, Andrew McCarthy, Xiangnan Dang, et al.. (2022). Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia. Journal of Parkinson s Disease. 12(6). 1991–2004. 7 indexed citations

Biglan, Kevin, Leanne Munsie, Kjell Svensson, et al.. (2021). Results of the Presence Study Evaluating Mevidalen for the Treatment of Lewy Body Dementia (LBD) (2028). Neurology. 96(15_supplement). 1 indexed citations

Chandler, Julie, et al.. (2021). Characteristics of Parkinson’s Disease in Patients with and without Cognitive Impairment. Journal of Parkinson s Disease. 11(3). 1381–1392. 12 indexed citations

Biglan, Kevin, Leanne Munsie, Kjell Svensson, et al.. (2021). Safety and Efficacy of Mevidalen in Lewy Body Dementia: A Phase 2, Randomized, Placebo‐Controlled Trial. Movement Disorders. 37(3). 513–524. 26 indexed citations

Goldman, Jennifer G., Bradley F. Boeve, Melissa J. Armstrong, et al.. (2021). Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting. Alzheimer s Research & Therapy. 13(1). 111–122. 1 indexed citations

10.

Sherva, Richard, Alden L. Gross, Shubhabrata Mukherjee, et al.. (2020). Genome‐wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways. Alzheimer s & Dementia. 16(8). 1134–1145. 33 indexed citations

11.

Goldman, Jennifer G., Leah K. Forsberg, Bradley F. Boeve, et al.. (2020). Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimer s Research & Therapy. 12(1). 137–137. 34 indexed citations

12.

Fowler, Nicole R., Noll L. Campbell, Gerhardt Pohl, et al.. (2018). One‐Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study. Journal of the American Geriatrics Society. 66(5). 969–975. 34 indexed citations

13.

Nisenbaum, Laura, Fangyi Zhao, Brian A. Millen, et al.. (2016). Serotonin 2A Receptor SNP rs7330461 Association with Treatment Response to Pomaglumetad Methionil in Patients with Schizophrenia. Journal of Personalized Medicine. 6(1). 9–9. 14 indexed citations

14.

Ruble, Cara, Ryan M. Smith, John Calley, et al.. (2016). Genomic structure and expression of the human serotonin 2A receptor gene (HTR2A) locus: identification of novel HTR2A and antisense (HTR2A-AS1) exons. BMC Genetics. 17(1). 16–16. 29 indexed citations

15.

Saykin, Andrew J., Li Shen, Xiaohui Yao, et al.. (2015). Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. Alzheimer s & Dementia. 11(7). 792–814. 197 indexed citations

16.

Yao, Xiaohui, Jingwen Yan, Sungeun Kim, et al.. (2015). P1‐201: Genetic findings using ADNI multimodal quantitative phenotypes: A 2014 update. Alzheimer s & Dementia. 11(7S_Part_9). 1 indexed citations

17.

Gross, Alden L., Richard Sherva, Shubhabrata Mukherjee, et al.. (2014). Calibrating Longitudinal Cognition in Alzheimer's Disease Across Diverse Test Batteries and Datasets. Neuroepidemiology. 43(3-4). 194–205. 43 indexed citations

18.

Smith, Ryan M., Audrey C. Papp, Amy Webb, et al.. (2012). Multiple Regulatory Variants Modulate Expression of 5-Hydroxytryptamine 2A Receptors in Human Cortex. Biological Psychiatry. 73(6). 546–554. 57 indexed citations

19.

Nisenbaum, Laura, Leanne Munsie, Bonnie A. Fijal, et al.. (2011). P.1.a.012 Confirmation of association between genetic markers in 5HTR2A and response to mGLU2/3 agonist LY2140023 monohydrate in schizophrenia. European Neuropsychopharmacology. 21. S243–S244. 3 indexed citations

20.

Munsie, Leanne, Mike Reed, Cara Ruble, et al.. (2010). Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. The Pharmacogenomics Journal. 12(3). 246–254. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact